Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 1M | 1M | 1M |
| Gross Profit | 2M | 1M | 1M | 1M | 1M |
| Operating Income | 34K | -9K | 40K | -307K | -436K |
| EBITDA | -61K | 61K | 101K | -246K | -252K |
| Net Income | -72K | -107K | -70K | -406K | -523K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.066
+0.00% today
1Y Change
-42.61%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vycor Medical, Inc. (VYCO) is a Healthcare stock with listed on OTC. The stock last traded around $0.07 and down 42.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +17.2%, EPS growth of -260.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.2%, EPS -260.6%, free cash flow -133.4% with operating margin 1.8% and ROIC -1.1%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VYCO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYCO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VYCO Max Drawdown
-71.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VYCO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
+13.9% YoY
FY Net Income
-$523.5K
-29.0% YoY
Free Cash Flow
-$17.0K
+92.3% YoY
Revenue Growth
+17.2%
EPS Growth
-260.6%
Gross Margin
83.8%
Net Margin
-3.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 1M | 1M | 1M |
| Gross Profit | 2M | 1M | 1M | 1M | 1M |
| Operating Income | 34K | -9K | 40K | -307K | -436K |
| EBITDA | -61K | 61K | 101K | -246K | -252K |
| Net Income | -72K | -107K | -70K | -406K | -523K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 87K | 106K | 57K | 37K | 91K |
| Total Assets | 830K | 998K | 992K | 860K | 935K |
| Total Liabilities | 5M | 5M | 4M | 4M | 3M |
| Shareholder Equity | -4M | -4M | -3M | -3M | -2M |
| Total Debt | 1M | 1M | 1M | 994K | 868K |
| Net Debt | 1M | 952K | 1M | 957K | 777K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21K
+109.8% YoY
Capital Expenditures
38K
-1280.4% YoY
Free Cash Flow
17K
+92.3% YoY
Key ratios
Gross Margin
83.8%
Operating Margin
1.8%
Net Margin
-3.9%
ROE
1.8%
Debt / Equity
-0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.